Thomson Reuters has launched the Newport Biologics Module, a source of competitive intelligence for biologic and biosimilar drugs.
The Newport Biologics Module, an addition to the Thomson Reuters Newport Premium solution, allows generic drug companies, biotech firms, or manufacturers of active pharmaceutical ingredients (API) to assess opportunities to enter the biosimilars market or to spot potential competitive activity.
The module provides a manufacturing process data covering biologic drugs, including recombinant proteins, antibodies, factors, and vaccines. Companies pursuing biosimilar opportunities can analyze multiple potential bio-manufacturing processes for each drug, genetic sequences, process steps, starting materials, and equipment required, as well as review related patents and literature.